Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Author:

Perrot Aurore1ORCID,Lauwers-Cances Valerie2,Corre Jill34,Robillard Nelly5,Hulin Cyrille6,Chretien Marie-Lorraine7,Dejoie Thomas8,Maheo Sabrina34,Stoppa Anne-Marie9,Pegourie Brigitte10,Karlin Lionel11,Garderet Laurent12,Arnulf Bertrand13,Doyen Chantal14,Meuleman Nathalie15,Royer Bruno16,Eveillard Jean-Richard17,Benboubker Lotfi18,Dib Mamoun19,Decaux Olivier20,Jaccard Arnaud21,Belhadj Karim22,Brechignac Sabine23,Kolb Brigitte24,Fohrer Cecile25,Mohty Mohamad12,Macro Margaret26,Richardson Paul G.27,Carlton Victoria28,Moorhead Martin28,Willis Tom28,Faham Malek28,Anderson Kenneth C.27,Harousseau Jean-Luc29,Leleu Xavier30,Facon Thierry31,Moreau Philippe32,Attal Michel33,Avet-Loiseau Hervé34,Munshi Nikhil27

Affiliation:

1. Hematology Department, University Hospital, Nancy, France;

2. Epidemiology and Statistics Department, University Hospital, Toulouse, France;

3. Myeloma Genomics Lab University Cancer Institute Toulouse (IUCT)-Oncopole, Cancer Research Center of Toulouse (CRCT), INSERM 1037, Toulouse, France;

4. Université Paul Sabatier, Toulouse, France;

5. Hematology Laboratory, University Hospital, Nantes, France;

6. Hematology Department, University Hospital, Bordeaux, France;

7. Hematology Department, University Hospital, Dijon, France;

8. Biochemistry Laboratory, University Hospital, Nantes, France;

9. Hematology Department, Institut Paoli Calmettes, Marseille, France;

10. Hematology Department, University Hospital, Grenoble, France;

11. Hematology Department, University Hospital, Lyon, France;

12. Hematology Department, Saint-Antoine University Hospital, Paris, France;

13. Hematology Department, Saint-Louis University Hospital, Paris, France;

14. Hematology Department, Centre Hospitalier Universitaire (CHU) Université Catholique de Louvain (UCL) Namur, Yvoir, Belgium;

15. Hematology Department, Institut Jules Bordet (ULB), Brussels, Belgium;

16. Hematology Department, University Hospital, Amiens, France;

17. Hematology Department, University Hospital, Brest, France;

18. Hematology Department, University Hospital, Tours, France;

19. Hematology Department, University Hospital, Angers, France;

20. Hematology Department, University Hospital, Rennes, France;

21. Hematology Department, University Hospital, Limoges, France;

22. Hematology Department, University Hospital, Creteil, France;

23. Hematology Department, University Hospital, Bobigny, France;

24. Hematology Department, University Hospital, Reims, France;

25. Hematology Department, University Hospital, Strasbourg, France;

26. Hematology Department, University Hospital, Caen, France;

27. Hematology Department, Dana-Farber Cancer Institute, Boston, MA;

28. Adaptive Biotechnologies, Seattle, WA;

29. Hematology Department, Clinique du Confluent, Nantes, France;

30. Hematology Department, University Hospital, Poitiers, France;

31. Hematology Department, University Hospital, Lille, France;

32. Hematology Department, University Hospital, Nantes, France; and

33. Hematology Department, University Hospital, Toulouse, France

Abstract

Key Points MRD using NGS-identified patients with an excellent outcome in multiple myeloma. MRD should be assessed in every prospective trial, and is a candidate to become a primary end point.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3